Stealth BioTherapeutics Corp (NASDAQ: MITO) presented new data demonstrating the potential synergistic relationship between elamipretide and an exon-skipping phosphorodiamidate morpholino oligomer (PMO) in the X-linked muscular dystrophy (mdx) animal model.

• The data were presented at the 2022 Muscular Dystrophy Association and Clinical and Scientific Conference.

• Mitochondrial dysfunction has been observed early in the progression of Duchenne muscular dystrophy (DMD).

• It contributes to impaired energy homeostasis and inflammatory signaling in DMD.

• Read Next: Stealth Bio Stock Falls On FDA Refusal to File Letter For Barth Syndrome Candidate.

• As PMO efficacy has been shown to be energy-dependent, the study tested the hypothesis that improving mitochondrial function with the mitochondria-targeting elamipretide would enhance PMO efficacy.

• Results from the 7-week study demonstrated that the combination of weekly PMO and daily elamipretide therapies produced more than double the mean level of dystrophin protein in muscles compared to PMO alone.

• The data highlight the PMO/elamipretide combo therapy as a potential treatment for patients with DMD.

• In December, Stealth Bio concluded the pre-IND meeting for the DMD development program, including aligning on Stealth's proposal to assess the progression of myocardial fibrosis as a surrogate endpoint for its planned clinical trial.

• Price Action: MITO shares closed 11.1% at $0.64 during after-hours trading on Wednesday.

See more from Benzinga

• Roche's Evrysdi Shows Long-Term Efficacy, Safety In Broader Spinal Muscular Atrophy Population

• FDA Lifts Clinical Hold On Aprea's Relapsed/Refractory Blood Cancer Studies

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.